Ursodeoxycolic acid for the prevention of relapsing complications after gallstone acute pancreatitis, a double-blind multicenter randomized-controlled trial.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518237-28-00

Enrollment

332

Registered

2024-12-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrence of acute biliary pancreatitis

Brief summary

Death and / or complication associated with gallstones (new episode of PAB, cholangitis, cholecystitis, choledocholithiasis or biliary colic, variable based on the primary endpoint of the PONCHO clinical trial (1)), until cholecystectomy is performed or until 1 year.

Interventions

DRUGURSOBILANE 300 mg cápsulas.

DRUGExcipiente número 1 para cápsulas 500 gramos

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Death and / or complication associated with gallstones (new episode of PAB, cholangitis, cholecystitis, choledocholithiasis or biliary colic, variable based on the primary endpoint of the PONCHO clinical trial (1)), until cholecystectomy is performed or until 1 year.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026